{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:28:13Z","timestamp":1791430093520,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA210637"],"award-info":[{"award-number":["CA210637"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA206444"],"award-info":[{"award-number":["CA206444"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA183459"],"award-info":[{"award-number":["CA183459"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA200466"],"award-info":[{"award-number":["CA200466"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA127297"],"award-info":[{"award-number":["CA127297"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA217798"],"award-info":[{"award-number":["CA217798"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Differential expression of mucins has been associated with several cancers including colorectal cancer (CRC). In normal physiological conditions, secretory mucin MUC5AC is not expressed in the colonic mucosa, whereas its aberrant expression is observed during development of colon cancer and its precursor lesions. To date, the molecular mechanism of MUC5AC in CRC progression and drug resistance remains obscure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MUC5AC expression was determined in colon tissue microarray by immunohistochemistry. A RNA interference and CRISPR\/Cas9-mediated system was used to knockdown\/knockout the MUC5AC\u00a0in CRC cell lines to delineate its role in CRC tumorigenesis using in vitro functional assays and in vivo (sub-cutaneous and colon orthotopic) mouse\u00a0models. Finally, CRC cell lines and xenograft models were used to identify the mechanism of action of MUC5AC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overexpression of MUC5AC is observed in CRC patient tissues and cell lines. MUC5AC expression resulted in enhanced cell invasion and migration, and decreased apoptosis of CRC cells. MUC5AC interacted with CD44 physically, which was accompanied by the activation of Src signaling. Further, the presence of MUC5AC resulted in enhanced tumorigenesis and appearance of metastatic lesions in orthotopic mouse model. Additionally, up-regulation of MUC5AC resulted in resistance to 5-fluorouracil (5-FU) and oxaliplatin, and its knockout increased sensitivity to these drugs. Finally, we observed that up-regulation of MUC5AC conferred resistance to 5-FU through down-regulation of p53 and its target gene\n                      <jats:italic>p21<\/jats:italic>\n                      and up-regulation of \u03b2-catenin and its target genes\n                      <jats:italic>CD44<\/jats:italic>\n                      and\n                      <jats:italic>Lgr5.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that differential expression of secretory mucin MUC5AC results in enhanced tumorigenesis and also confers chemoresistance via CD44\/\u03b2-catenin\/p53\/p21 signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-020-01156-y","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T03:02:41Z","timestamp":1582599761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance"],"prefix":"10.1186","volume":"19","author":[{"given":"Ramesh","family":"Pothuraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayana","family":"Rachagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Ram","family":"Krishn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Krishna","family":"Nimmakayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koelina","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imayavaramban","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhwinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-9317","authenticated-orcid":false,"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177\u201393.","journal-title":"CA Cancer J Clin"},{"key":"1156_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MCG.0000000000001050","volume":"53","author":"Y Niv","year":"2019","unstructured":"Niv Y, Rokkas T. Mucin expression in colorectal Cancer (CRC): systematic review and meta-analysis. J Clin Gastroenterol. 2019;53:434\u201340.","journal-title":"J Clin Gastroenterol"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.canlet.2016.02.016","volume":"374","author":"SR Krishn","year":"2016","unstructured":"Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, et al. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett. 2016;374:304\u201314.","journal-title":"Cancer Lett"},{"key":"1156_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10555-019-09781-w","volume":"38","author":"IS Reynolds","year":"2019","unstructured":"Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer Metastasis Rev. 2019;38:237\u201357.","journal-title":"Cancer Metastasis Rev"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1245\/s10434-010-1338-z","volume":"18","author":"H Kang","year":"2011","unstructured":"Kang H, Min BS, Lee KY, Kim NK, Kim SN, Choi J, Kim H. Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol. 2011;18:711\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1156_CR6","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1002\/pmic.200800040","volume":"8","author":"S Yonezawa","year":"2008","unstructured":"Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008;8:3329\u201341.","journal-title":"Proteomics"},{"key":"1156_CR7","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1038\/s41598-017-04952-7","volume":"7","author":"HP Hsu","year":"2017","unstructured":"Hsu HP, Lai MD, Lee JC, Yen MC, Weng TY, Chen WC, Fang JH, Chen YL. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. Sci Rep. 2017;7:5823.","journal-title":"Sci Rep"},{"key":"1156_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/carcin\/bgy019","volume":"39","author":"SR Krishn","year":"2018","unstructured":"Krishn SR, Ganguly K, Kaur S, Batra SK. Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view. Carcinogenesis. 2018;39:633\u201351.","journal-title":"Carcinogenesis"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ajg.2016.482","volume":"112","author":"S Kaur","year":"2017","unstructured":"Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, Krishn SR, Mallya K, Aithal A, Sasson AR, et al. A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic Cancer: a multicenter study. Am J Gastroenterol. 2017;112:172\u201383.","journal-title":"Am J Gastroenterol"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0169-409X(01)00115-6","volume":"48","author":"K Khanvilkar","year":"2001","unstructured":"Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Rev. 2001;48:173\u201393.","journal-title":"Adv Drug Deliv Rev"},{"key":"1156_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-16-0862","volume":"23","author":"CV Rao","year":"2017","unstructured":"Rao CV, Janakiram NB, Mohammed A. Molecular pathways: Mucins and drug delivery in Cancer. Clin Cancer Res. 2017;23:1373\u20138.","journal-title":"Clin Cancer Res"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/oncsis.2013.35","volume":"2","author":"D Ahmed","year":"2013","unstructured":"Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2:e71.","journal-title":"Oncogenesis"},{"key":"1156_CR13","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/0008-5472.CAN-04-0975","volume":"64","author":"HR Li","year":"2004","unstructured":"Li HR, Shagisultanova EI, Yamashita K, Piao Z, Perucho M, Malkhosyan SR. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res. 2004;64:4760\u20137.","journal-title":"Cancer Res"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/onc.2015.478","volume":"35","author":"I Lakshmanan","year":"2016","unstructured":"Lakshmanan I, Rachagani S, Hauke R, Krishn SR, Paknikar S, Seshacharyulu P, Karmakar S, Nimmakayala RK, Kaushik G, Johansson SL, et al. MUC5AC interactions with integrin beta4 enhances the migration of lung cancer cells through FAK signaling. Oncogene. 2016;35:4112\u201321.","journal-title":"Oncogene"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/002215540405200213","volume":"52","author":"N Moniaux","year":"2004","unstructured":"Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, Wittel UA, Andrianifahanana M, Aubert JP, Batra SK. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004;52:253\u201361.","journal-title":"J Histochem Cytochem"},{"key":"1156_CR16","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1038\/oncsis.2016.12","volume":"5","author":"S Chaudhary","year":"2016","unstructured":"Chaudhary S, Madhukrishna B, Adhya AK, Keshari S, Mishra SK. Overexpression of caspase 7 is ERalpha dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip). Oncogenesis. 2016;5:e219.","journal-title":"Oncogenesis"},{"key":"1156_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","volume":"38","author":"R Vengoji","year":"2019","unstructured":"Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38:266.","journal-title":"J Exp Clin Cancer Res"},{"key":"1156_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1053\/j.gastro.2018.05.041","volume":"155","author":"RK Nimmakayala","year":"2018","unstructured":"Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S, Chugh S, Karmakar S, Rauth S, Vengoji R, Atri P, Talmon GA, et al. Cigarette smoke induces stem cell features of pancreatic Cancer cells via PAF1. Gastroenterology. 2018;155:892\u2013908 e896.","journal-title":"Gastroenterology"},{"key":"1156_CR19","first-page":"142","volume":"2014","author":"N Jonckheere","year":"1846","unstructured":"Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 1846;2014:142\u201351.","journal-title":"Biochim Biophys Acta"},{"key":"1156_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64.","journal-title":"J Hematol Oncol"},{"key":"1156_CR21","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.cellsig.2015.05.002","volume":"27","author":"K Nam","year":"2015","unstructured":"Nam K, Oh S, Lee KM, Yoo SA, Shin I. CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cell Signal. 2015;27:1882\u201394.","journal-title":"Cell Signal"},{"key":"1156_CR22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.18632\/genesandcancer.108","volume":"7","author":"P Pai","year":"2016","unstructured":"Pai P, Rachagani S, Dhawan P, Sheinin YM, Macha MA, Qazi AK, Chugh S, Ponnusamy MP, Mallya K, Pothuraju R, Batra SK. MUC4 is negatively regulated through the Wnt\/beta-catenin pathway via the notch effector Hath1 in colorectal cancer. Genes Cancer. 2016;7:154\u201368.","journal-title":"Genes Cancer"},{"issue":"Pt 3","key":"1156_CR23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.106.3.771","volume":"106","author":"T Lesuffleur","year":"1993","unstructured":"Lesuffleur T, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, Zweibaum A. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J Cell Sci. 1993;106(Pt 3):771\u201383.","journal-title":"J Cell Sci"},{"key":"1156_CR24","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-16-2530","volume":"23","author":"I Lakshmanan","year":"2017","unstructured":"Lakshmanan I, Salfity S, Seshacharyulu P, Rachagani S, Thomas A, Das S, Majhi PD, Nimmakayala RK, Vengoji R, Lele SM, et al. MUC16 regulates TSPYL5 for lung Cancer cell growth and Chemoresistance by suppressing p53. Clin Cancer Res. 2017;23:3906\u201317.","journal-title":"Clin Cancer Res"},{"key":"1156_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.biolcel.2003.12.005","volume":"96","author":"E Leteurtre","year":"2004","unstructured":"Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, Huet G, Lesuffleur T. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell. 2004;96:145\u201351.","journal-title":"Biol Cell"},{"key":"1156_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"1156_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s12276-018-0128-8","volume":"50","author":"L He","year":"2018","unstructured":"He L, Zhu H, Zhou S, Wu T, Wu H, Yang H, Mao H, SekharKathera C, Janardhan A, Edick AM, et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp Mol Med. 2018;50:101.","journal-title":"Exp Mol Med"},{"key":"1156_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/jcp.54.3.210","volume":"54","author":"MB Pereira","year":"2001","unstructured":"Pereira MB, Dias AJ, Reis CA, Schmitt FC. Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues. J Clin Pathol. 2001;54:210\u20133.","journal-title":"J Clin Pathol"},{"key":"1156_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/modpathol.2013.101","volume":"26","author":"MD Walsh","year":"2013","unstructured":"Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol. 2013;26:1642\u201356.","journal-title":"Mod Pathol"},{"key":"1156_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00428-016-1970-5","volume":"469","author":"J Betge","year":"2016","unstructured":"Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, Ebert MP, Langner C. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch. 2016;469:255\u201365.","journal-title":"Virchows Arch"},{"key":"1156_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1756-9966-29-53","volume":"29","author":"S Yamazoe","year":"2010","unstructured":"Yamazoe S, Tanaka H, Sawada T, Amano R, Yamada N, Ohira M, Hirakawa K. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J Exp Clin Cancer Res. 2010;29:53.","journal-title":"J Exp Clin Cancer Res"},{"key":"1156_CR32","doi-asserted-by":"publisher","first-page":"30892","DOI":"10.1074\/jbc.M113.477158","volume":"288","author":"M Alam","year":"2013","unstructured":"Alam M, Ahmad R, Rajabi H, Kharbanda A, Kufe D. MUC1-C oncoprotein activates ERK-->C\/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J Biol Chem. 2013;288:30892\u2013903.","journal-title":"J Biol Chem"},{"key":"1156_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1757-2215-4-7","volume":"4","author":"MP Ponnusamy","year":"2011","unstructured":"Ponnusamy MP, Seshacharyulu P, Vaz A, Dey P, Batra SK. MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J Ovarian Res. 2011;4:7.","journal-title":"J Ovarian Res"},{"key":"1156_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2010.02.015","volume":"295","author":"M Mimeault","year":"2010","unstructured":"Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S, Batra SK. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem\/progenitor cells and their progenies. Cancer Lett. 2010;295:69\u201384.","journal-title":"Cancer Lett"},{"key":"1156_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2017.00018","volume":"5","author":"LT Senbanjo","year":"2017","unstructured":"Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of Cancer cells. Front Cell Dev Biol. 2017;5:18.","journal-title":"Front Cell Dev Biol"},{"key":"1156_CR36","doi-asserted-by":"publisher","first-page":"114095","DOI":"10.18632\/oncotarget.23125","volume":"8","author":"L Mayr","year":"2017","unstructured":"Mayr L, Pirker C, Lotsch D, Van Schoonhoven S, Windhager R, Englinger B, Berger W, Kubista B. CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model. Oncotarget. 2017;8:114095\u2013108.","journal-title":"Oncotarget"},{"key":"1156_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12885-018-3988-3","volume":"18","author":"M Hagiwara","year":"2018","unstructured":"Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H, Oya M. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer. 2018;18:113.","journal-title":"BMC Cancer"},{"key":"1156_CR38","doi-asserted-by":"crossref","unstructured":"Bourguignon LYW, Earle C, Shiina M. Activation of matrix Hyaluronan-mediated CD44 signaling, epigenetic regulation and Chemoresistance in head and neck Cancer stem cells. Int J Mol Sci. 2017;184:1912\u201319.","DOI":"10.3390\/ijms18091849"},{"key":"1156_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrc1251","volume":"4","author":"MA Hollingsworth","year":"2004","unstructured":"Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45\u201360.","journal-title":"Nat Rev Cancer"},{"key":"1156_CR40","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-07-6041","volume":"68","author":"P Chaturvedi","year":"2008","unstructured":"Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008;68:2065\u201370.","journal-title":"Cancer Res"},{"key":"1156_CR41","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/carcin\/bgs225","volume":"33","author":"S Rachagani","year":"2012","unstructured":"Rachagani S, Macha MA, Ponnusamy MP, Haridas D, Kaur S, Jain M, Batra SK. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis. 2012;33:1953\u201364.","journal-title":"Carcinogenesis"},{"key":"1156_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/sj.bjc.6604517","volume":"99","author":"MP Ponnusamy","year":"2008","unstructured":"Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer. 2008;99:520\u20136.","journal-title":"Br J Cancer"},{"key":"1156_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513\u201332.","journal-title":"Nat Rev Drug Discov"},{"key":"1156_CR44","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.1128\/MCB.21.20.6768-6781.2001","volume":"21","author":"E Sadot","year":"2001","unstructured":"Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol. 2001;21:6768\u201381.","journal-title":"Mol Cell Biol"},{"key":"1156_CR45","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1074\/jbc.M114.620252","volume":"290","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Geng L, Talmon G, Wang J. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem. 2015;290:6215\u201325.","journal-title":"J Biol Chem"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-020-01156-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T08:37:13Z","timestamp":1665909433000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01156-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01156-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Nebraska Medical Center, Nebraska, USA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SKB is one of the co-founders of Sanguine Diagnostics and Therapeutics, Inc. Other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}